Moderna: Oddo BHF lowers its target price

(CercleFinance.com) - While maintaining its 'outperform' opinion on Moderna, Oddo BHF has lowered its price target from $86 to $56, following the reduction of its short-term expectations and the adoption of a beta 'more in line with the biotech's risk'.


Recalling that Moderna published on Monday an update of both its 2024 and 2025 figures, as well as its pipeline, the research firm adjusts its revenue growth assumption over the 2024/28 period to 11%, from 17% initially.

Despite a perception that may be confused (biotech with development risk or pharma with sales), we continue to believe that the current valuation only marginally takes into account the breadth of the company's portfolio', the analyst moderates.

Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.